Monitoring blood conditions after stem cell transplantation using cell-free DNA analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. It aims to utilize cell-free DNA (cfDNA) profiling to monitor clinically relevant events such as graft-versus-host disease (GVHD), infections, and other complications post-transplant. By analyzing cfDNA methylation patterns, the study seeks to provide a more accurate and timely diagnosis of these conditions compared to traditional symptom-based methods. The research involves collecting blood samples for cfDNA and extracellular vesicle analysis to assess the patient's health status after transplantation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient must be affected by an hematological malignancy requiring hematopoietic stem cell transplantation (HSCT).

Exclusion Criteria:

* Patients can not be 17 years old or yunger

Where it's running

• Unità di Ematologia e Trapianto di Midollo Osseo e Oncoematologia of the San Raffaele Hospital in Milan
  Milan, Milan, Italy Recruiting
• SS Trapianto allogenico e terapie cellulari, SC Ematologia U of the Città della Salute e della Scienza Hospital
  Turin, Turin, Italy Recruiting

Study contacts

• Study coordinator: Silvia Deaglio, MD/PhD
• Email: silvia.deaglio@unito.it
• Phone: +39 0116709535

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

• Post transplant cyclophosphamide, bortezomib, and sitagliptin to prevent graft-versus-host disease after allogeneic transplantation

  This study tests whether a combination of post-transplant cyclophosphamide, bortezomib, and sitagliptin can prevent GvHD in adults undergoing reduced-intensity allogeneic stem cell transplantation from matched related or unrelated donors.

  Recruiting Phase 1/2 Northwell Health · New Hyde Park, New York · NCT07675174

• Psychiatric Symptoms and Quality of Life in Graft-versus-Host Disease

  This project will see if psychiatric symptoms like depression are linked to GvHD symptom severity and health-related quality of life in adults with graft-versus-host disease.

  Recruiting Medical University of Gdansk · Gdansk, Pomeranian Voivodeship · NCT07314892

• Lowering the total dose of cyclophosphamide after haploidentical stem cell transplant for blood cancers

  This trial tests whether a reduced total dose of cyclophosphamide after a haploidentical stem cell transplant can improve outcomes for adults with blood cancers.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Paris · NCT07193420

• Comparing Ruxolitinib with Steroids for Chronic Graft-versus-Host Disease Treatment

  This study is testing if a new treatment combining Ruxolitinib with steroids can help people with moderate to severe chronic graft-versus-host disease feel better compared to just using steroids alone.

  Recruiting Phase 2 Seoul St. Mary's Hospital · Seoul, Banpo-daero/Seocho-gu · NCT06756061

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.